Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 13 clinical trials
Study of Subcutaneous Risankizumab Injection Compared to Oral Apremilast Tablets to Assess Change in Disease Activity And Adverse Events in Adult Participants With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy

Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is

plaque psoriasis
systemic therapy
apremilast
risankizumab
arthritis
  • 9 views
  • 22 Sep, 2021
  • 67 locations
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

suboptimal response may benefit from switching to risankizumab with regard to skin symptoms, quality of life symptoms and psoriasis symptoms. Study duration will last for up to 64 weeks with

secukinumab
ixekizumab
  • 49 views
  • 03 Jul, 2021
  • 81 locations
A Study of Subcutaneous Risankizumab Injection for Pediatric Participants With Moderate to Severe Plaque Psoriasis to Assess Change in Disease Symptoms

treatment in pediatric patients and this study is being done to evaluate risankizumab in pediatric participants with moderate to severe plaque psoriasis. This study will assess the change in disease

plaque psoriasis
systemic therapy
inflammatory disease
ustekinumab
risankizumab
  • 17 views
  • 19 Sep, 2021
  • 72 locations
A Multicenter Randomized Double-Blind Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis

The objectives of Sub-Study 1 are to evaluate the efficacy, safety, and pharmacokinetics of risankizumab as induction treatment in subjects with moderately to severely active ulcerative colitis

remission
  • 618 views
  • 19 Sep, 2021
  • 927 locations
Study of Subcutaneous (Injected Under the Skin) Risankizumab to Assess Change in Disease Symptoms in Adult Participants With Moderate to Severe Plaque Psoriasis With Palmoplantar Involvement

attacks healthy tissue by mistake. Palmoplantar (non-pustular) plaque psoriasis (PPPsO) represents a localized form of psoriasis in palms and soles. This study will evaluate how safe risankizumab is for

plaque psoriasis
systemic therapy
risankizumab
inflammatory disease
phototherapy
  • 0 views
  • 20 Sep, 2021
  • 70 locations
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. This study will evaluate how well risankizumab works compared to ustekinumab. This

crohn's disease
tumour necrosis
tumor necrosis factor
abdominal pain
ustekinumab
  • 97 views
  • 22 Sep, 2021
  • 484 locations
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

the effect of repeated infusions of risankizumab on the pharmacokinetics of sensitive probe substrates of Cytochrome P450 (CYP) enzymes in participants with moderately to severely active UC or CD.

crohn's disease
vitamin
inflammatory bowel disease
colitis
aminosalicylate
  • 113 views
  • 31 Aug, 2021
  • 7 locations
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With Moderate to Severe Plaque Psoriasis

healthy tissue by mistake. The main objective of this study is to assess maternal, fetal, and infant outcomes of women who are exposed to risankizumab during pregnancy with those in an unexposed

skin disorder
tumor necrosis factor
plaque psoriasis
risankizumab
  • 0 views
  • 16 Aug, 2021
  • 2 locations
Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

This study will assess the use of risankizumab in adult patients with moderate to severe chronic plaque psoriasis and compare risankizumab to other commonly used biologics.

  • 93 views
  • 28 Jun, 2021
  • 345 locations
Study to Assess Adverse Events When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Real World Setting

assess how safe risankizumab is compared to other therapies in treating adult participants with psoriasis in real world setting in the United States. Adverse events will be assessed using secondary

plaque psoriasis
risankizumab
  • 0 views
  • 05 Jul, 2021
  • 1 location